Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.33 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | PRKCA | P17252 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1685633 | 0.88 | LMNA (0.33) | LMNA | |
| SCHEMBL1685701 | 0.86 | ALDH1A1 (0.37) | LMNAALDH1A1TSHR | |
| SCHEMBL1685671 | 0.85 | PRKCA (0.31) | PRKCA | |
| SCHEMBL2709838 | 0.84 | PRKCA (0.30) | PRKCA | |
| SCHEMBL1150168 | 0.81 | LMNA (0.51) | LMNAALDH1A1TP53MAPTTSHR | |
| SCHEMBL1150166 | 0.81 | LMNA (0.51) | LMNAALDH1A1TP53MAPTTSHR | |
| SCHEMBL1150163 | 0.81 | LMNA (0.51) | LMNAALDH1A1TP53MAPTTSHR | |
| SCHEMBL1685649 | 0.81 | LMNA (0.51) | LMNAALDH1A1TP53MAPTTSHR | |
| SCHEMBL1685648 | 0.81 | LMNA (0.51) | LMNAALDH1A1TP53MAPTTSHR | |
| SCHEMBL1685675 | 0.81 | PRKCA (0.33) | PRKCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1950208-B1 | PROCESS FOR PRODUCING 6,6-DIMETHYL-3-OXABICYCLO[3.1.0]HEXAN-2-ONE | SUMITOMO CHEMICAL CO (JP) | 2012-05-02 | — | — | EP | disclosed |
| US-7928253-B2 | Method of producing 6,6-dimethyl-3-oxabicyclo[3.1.0]hexan-2-one | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-04-19 | — | — | US | disclosed |
| US-20100168463-A1 | METHOD OF PRODUCING 6,6-DIMETHYL-3-OXABICYCLO[3.1.0]HEXAN-2-ONE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-07-01 | — | — | US | disclosed |
| EP-1950208-A1 | PROCESS FOR PRODUCING 6,6-DIMETHYL-3-OXABICYCLO[3.1.0]HEXAN-2-ONE | Sumitomo Chemical Company, Limited (JP) | 2008-07-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168463-A1 | METHOD OF PRODUCING 6,6-DIMETHYL-3-OXABICYCLO[3.1.0]HEXAN-2-ONE | CYP1B1, HACL2, CMA1 | LMNA 2892/4885ALDH1A1 147/4885CYP4F2 331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.